Biopharma · FDA Approvals · Stock

MPLT MapLight

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and e…

Assets on file: ML-007C-MA

Start live analysis of MPLT Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for MPLT, including recently decided ones.

December 2027

Dec 2027

~ Dec 2027

MPLTMapLight

ML-007C-MA: Phase 2 trial NCT06887192 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

March 2029

Mar 2029

~ Mar 2029

MPLTMapLight

ML-007C-MA: Phase 2 trial NCT07459660 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

February 2030

Feb 2030

~ Feb 2030

MPLTMapLight

ML-007C-MA: Phase 2 trial NCT07459647 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Recent first-hand events

Every first-hand event for MPLT, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Oct 15, 2026

03:24 PM

MPLTMapLight

ML-007C-MA · NCT07459647 registry update

countries: {'total_sites': 42, 'us_sites': 42} → {'total_sites': 45, 'us_sites': 45}

Trial registry changeClinicalTrials.gov

Sep 30, 2026

03:21 PM

MPLTMapLight

ML-007C-MA · NCT06887192 registry update

countries: {'total_sites': 55, 'us_sites': 34} → {'total_sites': 62, 'us_sites': 37}

Trial registry changeClinicalTrials.gov

Aug 13, 2026

08:51 PM

MPLTMapLight

MapLight reports positive Phase 2 ZEPHYR topline for ML-007C-MA in schizophrenia

Phase 2 ZEPHYR trial met its primary endpoint with statistically significant PANSS reduction at Week 5. The company plans an End-of-Phase 2 FDA meeting to discuss the registrational Phase 3 ZEPHYR-2 trial, with topline results expected in 2028.

Topline resultsSEC 8-K Open record2 updates